Page last updated: 2024-12-07

aucubin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Aucubin is an iridoid glycoside found in various plants, including Aucuba japonica, Plantago species, and Eucommia ulmoides. It exhibits diverse pharmacological activities, including anti-inflammatory, antioxidant, and neuroprotective effects. Aucubin's synthesis involves complex enzymatic reactions, starting with the precursor, geraniol. It is studied extensively due to its potential therapeutic applications, particularly in treating inflammatory conditions, neurological disorders, and oxidative stress-related diseases. Aucubin's anti-inflammatory action is attributed to its ability to inhibit the production of inflammatory mediators like nitric oxide and prostaglandins. Furthermore, its antioxidant properties protect cells against damage caused by free radicals. Research on aucubin focuses on understanding its mechanisms of action, optimizing its extraction and purification, and evaluating its efficacy in preclinical and clinical studies.'

Cross-References

ID SourceID
PubMed CID91458
CHEMBL ID514882
CHEBI ID69796
SCHEMBL ID381032
MeSH IDM0049296

Synonyms (54)

Synonym
ACON1_002452
nsc-407293
479-98-1
aucubin
C09771
(2s,3r,4s,5s,6r)-2-[[(1s,4ar,5s,7as)-5-hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-1-yl]oxy]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
(2s,3r,4s,5s,6r)-2-((1s,4ar,5r,7as)-5-hydroxy-7-hydroxymethyl-1,4a,5,7a-tetrahydro-cyclopenta[c]pyran-1-yloxy)-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
MEGXP0_001729
einecs 207-540-8
nsc 407293
1,4a,5,7a-tetrahydro-5-hydroxy-7-hydroxymethylcyclopenta(c)pyran-1-yl-beta-d-glucopyranoside
(1s-(1alpha,4aalpha,5alpha,7aalpha))-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta(c)pyran-1-yl-beta-d-glucopyranoside
NCGC00169833-01
LMPR0102070006
rhinanthin
smr001397339
MLS002473252
chebi:69796 ,
CHEMBL514882
(2s,3r,4s,5s,6r)-2-[[(1s,4ar,5s,7as)-5-hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-1-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
HMS3098B08
b-d-glucopyranoside, (1s,4ar,5s,7as)-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1-yl
A827419
unii-2g52gs8uml
2g52gs8uml ,
AKOS015896774
S5459
(1s,4ar,5s,7as)-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta(c)pyran-1-yl-.beta.-d-glucopyranoside
aucuboside
aucubin [mi]
HY-N0664
CS-5367
SCHEMBL381032
AC-33938
Q-100516
RJWJHRPNHPHBRN-FKVJWERZSA-N
.beta.-d-glucopyranoside, (1s,4ar,5s,7as)-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1-yl
(2s,3r,4s,5s,6r)-2-(((1s,4ar,5s,7as)-5-hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-1-yl)oxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
mfcd00136026
rhimantin
aucubin, primary pharmaceutical reference standard
aucubin, analytical standard
(2s,3r,4s,5s,6r)-2-{[(1s,4ar,5s,7as)-5-hydroxy-7-(hydroxymethyl)-1h,4ah,5h,7ah-cyclopenta[c]pyran-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
AS-74899
NCGC00169833-02
(2s,3r,4s,5s,6r)-2-((1s,4ar,5s,7as)-5-hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-1-yloxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
Q418014
aucubuside
DTXSID60963965
CCG-267985
(1s,4ar,5s,7as)-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1-yl beta-d-glucopyranoside
aucubin (constituent of chaste tree)
(1s,4ar,5s,7as)-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta(c)pyran-1-yl-beta-d-glucopyranoside
aucubine

Research Excerpts

Overview

Aucubin is an iridoid glycoside widely spread in the families Eucommia ulmoides Oliv., Aucuba japonica Thunb and Plantain asiatica. It exhibits various biological activities such as antioxidant, anti-inflammatory, and protecting the liver.

ExcerptReferenceRelevance
"Aucubin is an iridoid glycoside that is widely distributed in green plants and exhibits various biological activities such as antioxidant, anti-inflammatory, and protecting the liver. "( Dietary effects of aucubin on growth and flesh quality of grass carp (Ctenopharyngodon idellus) based on metabolomics.
Leng, X; Li, X; Tan, H; Xu, X; Xu, Z; Yang, H, 2022
)
2.49
"Aucubin is an iridoid glycoside widely spread in the families "( Characteristics, Isolation Methods, and Biological Properties of Aucubin.
Irawan, MA; Jayani, NIE; Kartini, K; Setiawan, F, 2023
)
2.59
"Aucubin is an iridoid glycoside that is widely prevalent in traditional medicinal herbs, such as Eucommia ulmoides Oliv., Aucuba japonica Thunb. "( A review of the pharmacology and toxicology of aucubin.
Guo, F; Ouyang, D; Zeng, X, 2020
)
2.26
"Aucubin (AU) is an iridoid glycoside and that is one of the active constituents of Eucommia ulmoides, has many pharmacological effects such as anti-inflammation, anti-liver fibrosis, and anti-atherosclerosis."( Neuroprotective effects of aucubin on hydrogen peroxide-induced toxicity in human neuroblastoma SH-SY5Y cells via the Nrf2/HO-1 pathway.
Cao, YJ; Hao, JC; He, XZ; Jing, HL; Li, Y; Li, YC; Shang, B; Tian, QQ; Wang, LJ; Wang, ZL; Yang, KL; Zhao, C, 2021
)
1.64
"Aucubin (AU) is an iridoid glycoside that has been shown to display estrogenic properties and has various pharmacological effects. "( Aucubin promotes angiogenesis via estrogen receptor beta in a mouse model of hindlimb ischemia.
Chen, L; Coffie, JW; Fang, Z; Gao, X; Geng, X; Li, C; Qiu, L; Song, M; Wang, H; Yang, Y; You, X; Zhang, L, 2017
)
3.34
"Aucubin is a natural constituent with a monoterpene cyclic ring system."( Aucubin Alleviates Bleomycin-Induced Pulmonary Fibrosis in a Mouse Model.
Duan, JX; Guan, CX; Guan, XX; Li, P; Liu, T; Liu, YP; Mei, WX; Ouyang, DS; Sun, GY; Wan, L; Zhong, WJ; Zhou, Y, 2017
)
2.62
"Aucubin (ACB) is an iridoid glycoside with various biological activities. "( Effect of aucubin on neural precursor cell survival during neuronal differentiation.
Han, M; Kim Kwon, Y; Song, M, 2018
)
2.33
"Aucubin (AUC) is a major bioactive ingredient in Eucommia ulmoides, Plantain asiatica, and Aucuba japonica, and has been shown to exert anti-inflammatory, antioxidative, and neuroprotective effects. "( Aucubin alleviates glial cell activation and preserves dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian mice.
Chen, X; Cui, C; Jia, XB; Shen, YQ; Sun, MF; Xu, YD; Xu, ZH; Yang, XS; Zhang, PH; Zhou, ZL; Zhu, YL, 2018
)
3.37
"Aucubin (AU) is an iridoid glycoside derived from Eucommia ulmoides that possesses anti-inflammatory and neuroprotective effects."( Aucubin Alleviates Seizures Activity in Li-Pilocarpine-Induced Epileptic Mice: Involvement of Inhibition of Neuroinflammation and Regulation of Neurotransmission.
Chen, L; Chen, S; Hu, K; Huang, Q; Huang, X; Li, C; Ouyang, DS; Wang, X; Zeng, G; Zeng, X; Zhou, L; Zong, W, 2019
)
2.68
"Aucubin is an active component extracted from Eucommia ulmoides, which has liver-protection effects."( Aucubin and its hydrolytic derivative attenuate activation of hepatic stellate cells via modulation of TGF-β stimulation.
Feng, H; Hu, K; Huang, WH; Li, XH; Lv, PY; Ouyang, DS; Qin, YH; Tian, YY; Wang, YQ; Zhou, HH, 2017
)
2.62
"Aucubin is an iridoid glycoside with a variety of pharmacological effects, such as antimicrobial and antiinflammatory, whilst also promoting dermal wound healing. "( Effects of aucubin on the healing of oral wounds.
Choi, SH; Jeong, MJ; Kang, SS; Shim, KM,
)
1.96

Effects

ExcerptReferenceRelevance
"Aucubin (AU) has been proven to exhibit highly effective anti-inflammatory activity, but its ability to protect against endometritis in dairy cows remains unclear."( Aucubin ameliorates the LPS-induced inflammatory response in bovine endometrial epithelial cells by inhibiting NF-κB and activating the Keap1/Nrf2 signalling pathway.
Cao, R; Feng, Y; Fu, K; Gao, F; Li, H; Tian, W, 2021
)
2.79

Actions

ExcerptReferenceRelevance
"Aucubin can enhance the anti-catabolic and anti-inflammatory effects of HA on OA chondrocytes."( The therapeutic effect of aucubin-supplemented hyaluronic acid on interleukin-1beta-stimulated human articular chondrocytes.
Chen, YR; Huang, TL; Liao, JY; Tang, Y; Yang, KC; Yang, SH, 2019
)
2.26

Treatment

Treatment with aucubin by both routes of administration ameliorated histopathological changes and reduced elevated serum markers of kidney injury. Aucubins significantly inhibited the production of MMP-1 by 57% when compared to UVB-irradiated cells.

ExcerptReferenceRelevance
"Aucubin treatment significantly reverses IL-1β-induced cytotoxicity and attenuated the IL-1β-induced chondrocyte apoptosis."( Aucubin Protects Chondrocytes Against IL-1β-Induced Apoptosis In Vitro And Inhibits Osteoarthritis In Mice Model.
Chen, PS; Jiang, Y; Wang, BW; Wang, SN; Yao, ZL; Yu, B, 2019
)
2.68
"Treatment with aucubin by both routes of administration ameliorated histopathological changes and reduced elevated serum markers of kidney injury."( Aucubin administered by either oral or parenteral route protects against cisplatin-induced acute kidney injury in mice.
Batičić, L; Broznić, D; Domitrović, R; Marinić, J; Potočnjak, I; Šimić, L, 2020
)
2.34
"Pretreatment with aucubin significantly inhibited the production of MMP-1 by 57% when compared to the UVB-irradiated cells."( Protective effects of aucubin isolated from Eucommia ulmoides against UVB-induced oxidative stress in human skin fibroblasts.
Cho, HY; Ho, JN; Hong, BS; Jun, WJ; Kim, HK; Lee, YH; Park, JS; Shin, DH, 2005
)
0.97
"Treatment of aucubin (1) with tert-butyldimethylsilyl chloride under alkaline conditions permitted regioselective silylation of either the primary hydroxyl groups at C-9 and C-6' or both primary hydroxyl groups and the secondary allylic hydroxyl group at C-6. "( Regioselective and stereospecific amination of iridoids: conversion of aucubin into aminoside antibiotic analogues.
Deguin, B; Koch, M; Laschiazza, R; Lecsö-Bornet, M; Rakotondramasy, VC; Tillequin, F, 2007
)
0.94

Pharmacokinetics

The established method was validated in terms of selectivity, linearity, accuracy, precision, recovery, stability. This method was successfully applied to the pharmacokinetic and tissue distribution studies of Aucubin, Ajugol and Catalpol in rat.

ExcerptReferenceRelevance
" A linear pharmacokinetic behavior was obtained after iv administation of 400-400 mg/kg of aucubin."( Pharmacokinetic study of an iridoid glucoside: aucubin.
Chang, IM; Kim, SK; Lee, MH; Shim, CK; Suh, NJ, 1991
)
0.76
" This simple LC-MS method was successfully applied in a pharmacokinetic study carried out in Sprague-Dawley rats after oral administration of aucubin at a single dose of 50 mg/kg."( A rapid and sensitive determination of aucubin in rat plasma by liquid chromatography-tandem mass spectrometry and its pharmacokinetic application.
Deng, Z; Guo, H; Ling, P; Xu, W, 2012
)
0.85
" Then this method was successfully applied to the pharmacokinetic study of geniposidic acid and aucubin after oral administration of Du-zhong tea extract to rats and the results indicated that this HPLC-MS/MS assay is a valuable method for the pharmacokinetic study of geniposidic acid and aucubin in rat plasma."( Development and validation of high liquid performance chromatography-tandem mass spectrometry method for simultaneous determination of geniposidic acid and aucubin in rat plasma for pharmacokinetic study after oral administration of Du-zhong tea extract.
Liu, Y; Ma, YL; Zhang, L; Zu, YG, 2014
)
0.82
" This method was successfully applied to the pharmacokinetic and tissue distribution studies of Aucubin, Ajugol and Catalpol in rat."( Pharmacokinetics and tissue distribution of Aucubin, Ajugol and Catalpol in rats using a validated simultaneous LC-ESI-MS/MS assay.
Li, X; Liu, M; Ma, B; Wang, C; Wu, X; Wu, Z; Xue, B; Zhang, Q; Zhu, J, 2015
)
0.9
" The established method was validated in terms of selectivity, linearity, accuracy, precision, recovery, stability, and applied to a pharmacokinetic study on type 1 diabetes model rats intraperitoneally administered with aucubin."( Determination of aucubin by supramolecular solvent-based dispersive liquid-liquid microextraction and UPLC-MS/MS: Application to a pharmacokinetic study in rats with type 1 diabetes.
Bai, D; Jiang, H; Lian, X; Ma, L; Ma, Q; Wang, N; Xue, H, 2020
)
1.08

Bioavailability

Aucubin is widely distributed in multiple organs including kidney, liver, heart, spleen and lung. Low oral bioavailability may be attributed to pH-instability in the gastric fluid.

ExcerptReferenceRelevance
" Therefore, the low oral bioavailability of aucubin may be attributed to pH-instability in the gastric fluid, poor GI absorption due to low lipophilicity, and the possible metabolism in the GI mucosa and liver (so called first-pass effect)."( Pharmacokinetic study of an iridoid glucoside: aucubin.
Chang, IM; Kim, SK; Lee, MH; Shim, CK; Suh, NJ, 1991
)
0.8
" AN could only be detected in the plasma and liver homogenate of normal mice, which was poorly absorbed in OVX mice and low in other measured tissues."( Pharmacokinetics and tissue distribution of five active ingredients of Eucommiae cortex in normal and ovariectomized mice by UHPLC-MS/MS.
An, J; Hu, F; Wang, C; Wang, Z; Yang, L; Zhang, Z, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Although aucubin has been shown to have poor oral bioavailability in rats, aucubin is widely distributed in multiple organs including kidney, liver, heart, spleen and lung, and there is a sex difference in the absorption of aucubin."( A review of the pharmacology and toxicology of aucubin.
Guo, F; Ouyang, D; Zeng, X, 2020
)
1.22

Dosage Studied

ExcerptRelevanceReference
" The influences of the factors, such as the dosage of coloring agent, reaction time, heating temperature and the dose of acid etc."( [Study on optimizing the analysis condition for active compound in Eucommia olive].
Lei, QF; Liu, JL; Peng, MJ; Zhang, M; Zhou, CS, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency0.06310.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency0.18360.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID334194Inhibition of classical complement pathway activation at 4 uM assessed as complement modulation test2003Journal of natural products, Jan, Volume: 66, Issue:1
Complement-inhibiting iridoids from Morinda morindoides.
AID1301498Cytotoxicity against human HT-29 cells by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii.
AID1251038Inhibition of COX1 (unknown origin) assessed as PGH2 production at 100 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID1301499Cytotoxicity against human Bel7402 cells by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii.
AID1301497Cytotoxicity against human A549 cells by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1251039Inhibition of COX2 (unknown origin) assessed as PGH2 production at 10 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID642415Estrogenic activity at ERalpha in human MVLN cells at 20 ug/mL after 24 hrs by luciferase reporter gene assay relative to E22012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery of estrogen receptor α modulators from natural compounds in Si-Wu-Tang series decoctions using estrogen-responsive MCF-7 breast cancer cells.
AID1251037Inhibition of COX1 (unknown origin) assessed as PGH2 production at 35 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID467894Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml measured after 72 hrs by luciferase reporter gene assay2009Journal of natural products, Dec, Volume: 72, Issue:12
Lamiridosins, hepatitis C virus entry inhibitors from Lamium album.
AID1251040Inhibition of COX2 (unknown origin) assessed as PGH2 production at 35 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID1301501Cytotoxicity against human A2780 cells by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii.
AID642414Estrogenic activity at ERalpha in human MVLN cells at 100 ug/mL after 24 hrs by luciferase reporter gene assay relative to E22012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery of estrogen receptor α modulators from natural compounds in Si-Wu-Tang series decoctions using estrogen-responsive MCF-7 breast cancer cells.
AID1301500Cytotoxicity against human BGC823 cells by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii.
AID1251041Inhibition of COX2 (unknown origin) assessed as PGH2 production at 100 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID334195Inhibition of classical complement pathway activation at 4 uM in presence of beta glucosidase by complement modulation test2003Journal of natural products, Jan, Volume: 66, Issue:1
Complement-inhibiting iridoids from Morinda morindoides.
AID1251036Inhibition of COX1 (unknown origin) assessed as PGH2 production at 10 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (155)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (5.81)18.7374
1990's6 (3.87)18.2507
2000's36 (23.23)29.6817
2010's68 (43.87)24.3611
2020's36 (23.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.88 (24.57)
Research Supply Index5.08 (2.92)
Research Growth Index5.19 (4.65)
Search Engine Demand Index61.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (2.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other156 (97.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]